Cargando…
Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
Monoclonal antibodies directed against interleukin (IL)‐5, such as mepolizumab and benralizumab, are an effective and established treatment for severe eosinophilic asthma. Here, we present a patient with eosinophilic asthma with a partial clinical response to mepolizumab initially, as measured by th...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013786/ https://www.ncbi.nlm.nih.gov/pubmed/33815803 http://dx.doi.org/10.1002/rcr2.742 |